INS and metabolic syndrome: In summary, siRNA nanoparticle targeting Usp20 exhibits a good therapeutic effect on metabolic diseases caused by a HFD or a high-cholesterol diet, with reduced lipid levels, decreased atherosclerosis, and increased thermogenesis and insulin sensitivity, demonstrating that siRNA targeting Usp20 holds great promise for treating metabolic syndrome.